清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.

作者
Laura Ann Huppert,Reshma L Mahtani,Samantha Catherine Fisch,Naomi G. Dempsey,Sarah Premji,Angelina Taylor,Saya Liz Jacob,Laura Quintal,Michelle Melisko,Amy Jo Chien,Ana Cristina Sandoval-Leon,Lauren Carcas,Manmeet Singh Ahluwalia,Natasha Harpalani,Jenna Elizabeth Hoppenworth,Dame W. Idossa,Ruta D. Rao,Karthik V. Giridhar,Hope S. Rugo
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 1083-1083 被引量:14
标识
DOI:10.1200/jco.2024.42.16_suppl.1083
摘要

1083 Background: T-DXd and SG are both FDA-approved treatments for patients (pts) with HER2-low MBC, but little data exists on the sequential use of these ADCs. Methods: In this multicenter retrospective cohort study, we identified pts with HER2-low MBC treated sequentially with both T-DXd and SG in either order, with or without intervening therapies (IntTx), at 5 academic centers between 2020-2023. We previously reported real-world progression free survival (rwPFS) and real-world overall survival (rwOS) by HR-status and ADC sequence order. Here we provide updated rwPFS and rwOS data, as well as new subgroup analyses by age, sites of disease, and use of IntTx between ADCs for HR- and HR+ disease. Results: 84 pts with HER2-low MBC treated with both T-DXd and SG were included, including 56 pts with HR+/HER2-low MBC (66.7%) and 28 pts with HR-/HER2-low MBC (33.3%). Prior to the start of ADC1, median age was 58 yrs and 22 pts were >65 yrs (26.2%), 65 pts (77.4%) had visceral disease, and 14 pts (16.7%) had central nervous system (CNS) disease. 36 pts (42.9%) had an IntTx between ADCs. Table 1 shows updated rwPFS and rwOS data by HR-status and ADC sequence order. For pts with HR+ and HR- MBC, there was no difference in ADC1 rwPFS or ADC2 rwPFS by age ≤65 vs. >65 yr or by presence vs. absence of visceral disease. For pts with HR- MBC, ADC1 rwPFS and rwOS was shorter for pts with CNS disease vs. pts without CNS disease (rwPFS 5.4 mo (n=6) vs. 8.5 mo (n=22), p=0.03; rwOS 11.6 mo vs. 21.1 mo, p<0.01 respectively). For pts with HR+ and HR- MBC, there was no difference in ADC2 rwPFS with or without receipt of IntTx. There was no difference in time to treatment failure for first IntTx vs. ADC2 if no InTx was given. Conclusions: This is one of the largest multicenter cohorts of pts treated with sequential ADCs for HER2-low MBC. Median rwPFS was longer for ADC1 than ADC2 in all subgroups, regardless of HR-status, ADC sequence order, age ≤65 or >65 yr, presence of visceral disease, or use of IntTx. Among pts with HR-/HER2-low MBC, pts with CNS disease had shorter ADC1 rwPFS and rwOS than pts without CNS disease. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
13秒前
大医仁心完成签到 ,获得积分0
14秒前
潇洒小海豚完成签到,获得积分10
16秒前
25秒前
42秒前
46秒前
淡定的夜云完成签到 ,获得积分10
50秒前
53秒前
58秒前
圈圈圆了发布了新的文献求助100
1分钟前
1分钟前
1分钟前
顺心的一德完成签到,获得积分10
1分钟前
圈圈圆了完成签到,获得积分10
1分钟前
1分钟前
yc关闭了yc的文献求助
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
高高从霜完成签到 ,获得积分10
1分钟前
2分钟前
开朗的尔蝶的应助被amiee采纳,获得10
2分钟前
2分钟前
冷酷冬卉完成签到,获得积分10
2分钟前
2分钟前
whc发布了新的文献求助10
2分钟前
2分钟前
2分钟前
小星河完成签到 ,获得积分10
2分钟前
itsnotover发布了新的文献求助10
2分钟前
3分钟前
itsnotover完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
007关注了科研通微信公众号
3分钟前
007关注了科研通微信公众号
3分钟前
搞怪的白云完成签到 ,获得积分0
3分钟前
3分钟前
3分钟前
充电宝的应助被007采纳,获得30
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577264
关于积分的说明 21852314
捐赠科研通 7788621
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880